(tert-butoxy)-N-[1-(pyrrolidinylcarbonyl)(4-piperidyl)]carboxamide | 899806-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (tert-butoxy)-N-[1-(pyrrolidinylcarbonyl)(4-piperidyl)]carboxamide
• 英文别名: Tert-butyl [1-(pyrrolidin-1-ylcarbonyl)piperidin-4-yl]carbamate；tert-butyl N-[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]carbamate
• CAS: 899806-31-6
• 化学式: C₁₅H₂₇N₃O₃
• mdl: MFCD15143204
• 分子量: 297.398
• InChiKey: VEADDTRQRUBZFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.866
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (tert-butoxy)-N-[1-(pyrrolidinylcarbonyl)(4-piperidyl)]carboxamide 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以100%的产率得到4-aminopiperidyl pyrrolidinyl ketone
  参考文献：
  名称：

  WO2006/76595

  摘要：

  公开号：
• 作为产物：
  描述：

  1-吡咯烷羰酰氯 、 4-叔丁氧羰基氨基哌啶 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以89%的产率得到(tert-butoxy)-N-[1-(pyrrolidinylcarbonyl)(4-piperidyl)]carboxamide
  参考文献：
  名称：

  WO2006/76595

  摘要：

  公开号：

文献信息

• Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
  申请人：Albers J. Ronald

  公开号：US20060287344A1

  公开（公告）日：2006-12-21

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供的是具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，以及包含有效量氨基嘌呤化合物的组合物和用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Albers Ronald J.

  公开号：US20090275564A1

  公开（公告）日：2009-11-05

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量氨基嘌呤化合物的组合物，以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者注射有效量的氨基嘌呤化合物。
• Methods of treatment and prevention using haloaryl substituted aminopurines
  申请人：Bennett L. Brydon

  公开号：US20080021048A1

  公开（公告）日：2008-01-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或通过抑制JNK通路可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。
• METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES
  申请人：Bennett Brydon L.

  公开号：US20100249066A1

  公开（公告）日：2010-09-30

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包括有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者中施用有效量的氨基嘌呤化合物。